# Effect of "Sekanjabin e Safarjali" (Quince Oxymel) in the Prevention of Migraine Attacks

> **NCT02179775** · NA · UNKNOWN · sponsor: **Shiraz University of Medical Sciences** · enrollment: 45 (estimated)

## Conditions studied

- Migraine Headache
- Gastric Diseases

## Interventions

- **DRUG:** propranolol
- **DRUG:** Quince's oxymel
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT02179775
- **Lead sponsor:** Shiraz University of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-07
- **Primary completion:** 2014-09
- **Final completion:** 2014-10
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2014-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02179775

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02179775, "Effect of "Sekanjabin e Safarjali" (Quince Oxymel) in the Prevention of Migraine Attacks". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02179775. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*